Use of Interferon Γ Gene Modified Dendritic Cells in Immunotherapy for Hepatic Cancer

薛刚,程莹,曹永宽,王培红,张国虎,龚加庆,黄文林,田伏洲
DOI: https://doi.org/10.11569/wcjd.v16.i25.2820
2008-01-01
Abstract:AIM: To construct an adenoviral vector expressing human interferon γ (IFNγ) for transfecting human monocyte-derived dendritic cells (Ad-IFNγ-DC), and then to detect the anti-hepatic cancer ability of whole cell lysates pulsed Ad-IFNγ-DC acting as adjuvant.METHODS: The recombinant adenoviral vector carrying IFNγ gene (Ad-IFNγ) was constructed and transfected into Ad-IFNγ-DC. After trans-fection, the IFNγ protein expression and cyto-kines secretion by DC were detected and DC phenotypes were assayed with flow cytometry; the phagocytic ability of DC was assayed using FITC-dextran uptake method. Subsequently, the capability of antigen pulsed Ad-IFNγ-DC to pro-mote T cell proliferation and differentiation was detected using 3H-TdR incorporation and RT-PCR/ELISA method respectively. Finally, the ability of T cells to kill HepG2 cells was detected with lactate dehydrogenase release assay. RESULTS: Ad-IFNγ did not impact the phago-cytic function of DC 24 h after transfection (F = 2.31, P = 0.13). DC transfected with Ad-IFNγ ex-pressed IFNγ protein successfully (P 0.01). An-tigen pulsed Ad-IFNγ-DC stimulated T cell pro-liferation and enhanced expression of interleu-kin-2 (IL-2) and T-bet from the T cells (P 0.01). Finally, the abilities of tumor antigen loaded Ad-IFNγ-DC primed T cells to kill HepG2 cells were 43.64% ± 3.51% and 48.87% ± 4.83% as the ratio of E/T was 20:1 and 50:1, respectively, which were stronger than those in the Ad-LacZ-DC and NTDC primed T cells (P 0.01). CONCLUSION: Ad-IFNγ transfection can pro-mote DC maturation, enhance its capacities of antigen presentation and T cell stimulation, induce Th1 polarization and strengthen anti-HepG2 cell immunities.
What problem does this paper attempt to address?